Froniter Science Foundation-Hellas

Yarchoan M. Hopkins A. Jaffee E.M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377: 2500-2501 Goodman AM, Kato S, Bazhenova L et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16:2598-2608. Litchfield K. Reading J.L. Puttick C. Thakkar K. Abbosh C. Bentham R. Watkins T.B.K. Rosenthal R. Biswas D. Rowan A. Lim E. Al Bakir M. Turati V. Guerra-Assunção J.A. Conde L.

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 A: Prevalence (%) of PD-L1 positive expression by histological subtype Note: A significant result is obtained for 25% and 50% cutoffs, between PD-L1 status and Histology. Respective p-values: 0.047 and 0.0083. B: Prevalence (%) of PD-L1 positive expression by stage category Fig.